key: cord-0871457-x5d38grs
authors: Adashi, Eli Y.; Cohen, I. Glenn
title: Antiviral Therapeutics: Key to Curbing the COVID-19 Pandemic
date: 2021-10-31
journal: Am J Med
DOI: 10.1016/j.amjmed.2021.10.013
sha: c4a2c30fb834064a854827f1a53f704997f2db0e
doc_id: 871457
cord_uid: x5d38grs

nan

Well-nigh two years into the SARS-CoV-2 pandemic, the successful abrogation of this global scourge appears increasingly uncertain. Confronted with a fourth wave of infections fueled by the highly transmissible delta variant, an exhausted planet stands bereft of a clear path forward. Left to ponder waning vaccine-mediated protection, attendant breakthrough infections, and vaccine boosters, governments the world over are in desperate search for solutions. Non-adherence to mitigation measures, anti-vaccination and masking sentiments, as well as growing pandemic fatigue, further compromise what is rapidly becoming an increasingly fragile state of affairs. It is against this backdrop that the growing import of potent antiviral therapeutics has become glaringly apparent. Calls to address this shortfall were recently issued by both the National Academy of Medicine and the Government Accountability Office. 1, 2 In this Commentary we review recent investments of the U.S. government in the development and procurement of short-and long-acting antiviral therapeutics in a quest to complement vaccines and hamper the pandemic.

It is becoming increasingly clear that vaccination and mitigation alone will not suffice if the SARS-CoV-2 pandemic is to be subdued. 1, 2 This recognition draws, in part, on the materialization of ever more potent, heretofore unrecognized viral mutants. 1,2 Aided by the multiple challenges of attaining nationwide (let alone global) herd immunity, viral mutants are bound to continue to evolve leaving ever more human devastation in their wake. 1,2, The outcome of an all-out race to develop vaccines at a pace that matches the viral mutation rate remains uncertain at best. What appears to be called for, at this time, is an investment in the heretofore absent short-and long-term antiviral therapeutics with an eye toward complementing and fortifying extant antiviral strategies. 1,2 Readily prescribed by primary care providers across the globe, antiviral therapeutics stand to make a world of difference. 1 concluded an agreement with AstraZeneca in support of the late-stage development of AZD7442 and the supply of 700,000 doses thereof. 5 An altogether unique therapeutic, AZD7442 constitutes a long-acting combination of two highly-modified human monoclonal antibodies the clinical efficacy of which is being assessed. Backed by a compelling body of pre-clinical data, AZD7442 is projected to afford long-term (6-12 months) protection against COVID-19 in a manner distinct from that rendered by a vaccine. 6 As seen by AstraZeneca, AZD7442 possesses the potential to offer almost immediate protection to those who are immunosuppressed, to prevent the acquisition of the disease, and to treat those who are already infected with the virus. 5 Recent results from a Phase III pre-exposure prophylaxis trial showed AstraZeneca's AZD7442 to have achieved a statistically significant reduction in the trial's primary endpoint i.e. the incidence of symptomatic COVID-19. 7 Subject to approval by the FDA, AZD7442 could well become the first long-acting anti-COVID-19 measure that is not a vaccine.

More recently, on June 9, 2021, the DHHS announced that it will procure "approximately 1.7 million [5-day] 8 Intent on enrolling ≤1,850 participants globally, the estimated primary completion date of this Phase 3 clinical trial is November 8, 2021. 9 Subject to the approval of Molnupiravir by the FDA, the federal government plans to allocate this therapeutic to states and U.S. territories. 8 Healthcare providers will be able to order the product directly from the distributor within those allocations. 8 While the U.S. and other highincome countries are leading the development charge, one must not lose sight of the global justice imperative. As previously noted for vaccines, commitments to supply low-and middleincome countries that are most in need often buckle under the weight of domestic politics.

With the federal government now firmly enmeshed in the development of short-and long-term antiviral therapeutics, the prospect of modifying the COVID-19 pandemic has been materially advanced. The benefits accrued need not be limited to the present. Extant breakthroughs could well serve as a first line of defense against future pathogens. Planning along these very lines, the American Rescue Plan Act of 2021 has further allocated up to $1.2 billion in support of the creation of collaborative drug discovery groups. 3 The latter, known as the Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern, will draw on the creativity of the national biomedical research community to engender "innovative antiviral drug discovery and development." 3 Focused at first on the coronaviruses, the AVIDD centers will, in time, redirect their focus onto other viruses with pandemic potential. 3 Forewarned is forearmed.

Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit

Government Accountability Office: COVID-19: Federal Efforts Accelerate Vaccine and Therapeutic Development, but More Transparency Needed on Emergency Use Authorizations

Biden Administration to Invest $3 Billion from American Rescue Plan as Part of COVID-19 Antiviral Development Strategy

Antiviral Program for Pandemics

AstraZeneca to supply the US with up to half a million additional doses of the potential COVID-19 antibody treatment AZD7442

Potently neutralizing and protective human antibodies against SARS-CoV-2

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19

Department of Health & Human Services. Biden Administration announces U.S. government procurement of Merck's investigational antiviral medicine for COVID-19 treatment

Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)